Key result
Older age in PAH links to worse clinical outcomes and poorer response to targeted therapy.
Why the study?
Epidemiologic changes have defined an emerging phenotype of elderly individuals with PAH and increased risk predictors for left heart disease, but comprehensive insights on their characteristics, prognosis, and therapeutic response were needed.
Does PAH-targeted therapy have different efficacy and safety in elderly individuals with PAH compared to younger patients?
Systematic Review
Does PAH-targeted therapy have different efficacy and safety in elderly individuals with PAH compared to younger patients?
Elderly patients with PAH represent a distinct phenotype characterized by worse clinical outcomes, reduced exercise capacity, and poorer response to targeted therapies compared to younger patients.
Clinicians should anticipate reduced PAH therapy response in elderly patients; extends observational data and supports age-specific trials.
(1) Introduction. Although pulmonary arterial hypertension (PAH) usually affects young people with a low cardiovascular risk profile, progressive epidemiologic changes have been providing a codified phenotype of elderly subjects with PAH and increased risk predictors for left heart disease. We therefore conducted a systematic review to describe the current knowledge and characteristics of elderly individuals with PAH and further insights concerning their prognostic outcomes and therapeutic response. (2) Methods. A search was conducted in PubMed, Embase, and Cochrane Library for publications evaluating the epidemiology, diagnostic work-up, and treatment of PAH in elderly subjects. (3) Among the 74 publications initially retrieved, 16 full-text articles were selected for the present systematic review. Compared to their younger counterparts, elderly individuals with PAH showed greater clinical deterioration, reduced exercise capacity, and worse prognostic outcomes, as well as less response to PAH-targeted therapy and higher rates of PAH drug discontinuation. (4) Conclusions. Demographic changes over time contributed to define a peculiar PAH phenotype in elderly patients, with an increased burden of cardiovascular comorbidities and distinctive features compared to young patients. Further investigations are needed in order to better clarify the nosologic criteria, and management in this subset population.
No takes yet. Share an insight, caveat, or question.
Scagliola et al. (2023) conducted a systematic review in Pulmonary Arterial Hypertension. Elderly age vs. Younger age was evaluated on Clinical deterioration, exercise capacity, prognostic outcomes, and response to therapy. Elderly individuals with pulmonary arterial hypertension exhibited greater clinical deterioration, worse prognostic outcomes, and less response to PAH-targeted therapy compared to younger patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: